What is Leerink Partnrs’ Estimate for REGENXBIO Q1 Earnings?

REGENXBIO Inc. (NASDAQ:RGNX) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for REGENXBIO in a research note issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar anticipates that the biotechnology company will earn $0.65 per share for the quarter. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO’s Q3 2025 earnings at $2.03 EPS and Q4 2025 earnings at ($1.44) EPS.

A number of other equities analysts have also weighed in on RGNX. Chardan Capital reiterated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a report on Thursday, March 20th. The Goldman Sachs Group reduced their target price on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday. Raymond James initiated coverage on REGENXBIO in a research note on Friday, February 7th. They set an “outperform” rating and a $27.00 price target for the company. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th. Finally, HC Wainwright decreased their target price on REGENXBIO from $36.00 to $34.00 and set a “buy” rating for the company in a report on Monday, March 17th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, REGENXBIO presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.63.

REGENXBIO Stock Performance

REGENXBIO stock opened at $5.94 on Thursday. The company has a market cap of $297.69 million, a price-to-earnings ratio of -1.18 and a beta of 1.26. REGENXBIO has a 1 year low of $5.04 and a 1 year high of $17.52. The firm has a 50 day moving average price of $6.81 and a 200 day moving average price of $8.15.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The company had revenue of $21.21 million during the quarter, compared to analysts’ expectations of $23.70 million.

Institutional Investors Weigh In On REGENXBIO

Hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. raised its holdings in REGENXBIO by 67.0% during the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company’s stock worth $31,975,000 after buying an additional 1,659,206 shares during the period. Millennium Management LLC raised its holdings in shares of REGENXBIO by 406.3% during the fourth quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company’s stock valued at $10,222,000 after acquiring an additional 1,061,187 shares during the period. Adage Capital Partners GP L.L.C. purchased a new stake in shares of REGENXBIO in the 4th quarter valued at approximately $3,865,000. Norges Bank acquired a new position in REGENXBIO in the 4th quarter worth approximately $3,474,000. Finally, Cubist Systematic Strategies LLC purchased a new position in REGENXBIO during the 4th quarter worth approximately $2,793,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.